Costs of paediatric diabetes care in Germany: current situation and comparison with the year 2000

C C Bächle1, R W Holl, K Straßburger

  • 1Institute of Biometrics and Epidemiology, German Diabetes Centre, Leibniz Center at the Heinrich Heine University, Düsseldorf, Germany. christina.baechle@ddz.uni-duesseldorf.de

Insights

Direct costs for pediatric Type 1 diabetes care in Germany rose significantly between 2000 and 2007. This increase in healthcare spending for children with diabetes reflects new treatments and rising prevalence.

Area of Science:

  • Pediatric Endocrinology
  • Health Economics
  • Diabetes Management

Background:

  • Type 1 diabetes is a chronic condition requiring ongoing medical care for children.
  • Estimating the direct costs of pediatric diabetes care is crucial for resource allocation and policy-making.
  • Previous cost estimations for German pediatric diabetes care exist for the year 2000.

Purpose of the Study:

  • To determine the direct costs associated with pediatric Type 1 diabetes care in Germany for 2007.
  • To identify factors influencing these costs.
  • To compare the 2007 costs with those from 2000.

Main Methods:

  • Utilized clinical data and healthcare charges from 14,185 children (<20 years) with diabetes from a nationwide patient registry (DPV).
  • Monetized healthcare utilization using statutory health insurance fees and prices.
  • Analyzed cost associations with age, sex, migration background, diabetes duration, and metabolic control using regression models.

Main Results:

  • Mean direct diabetes-associated costs per child were €3524 in 2007.
  • Major cost drivers included hospitalization (32%), glucose self-monitoring (29%), insulin pump therapy (18%), and insulin (15%).
  • Total direct costs for pediatric diabetes care in Germany exceeded €110 million in 2007, a 47% increase from 2000.

Conclusions:

  • Direct costs for pediatric Type 1 diabetes care in Germany increased between 2000 and 2007.
  • This rise is likely attributed to the adoption of new therapeutic strategies and an increased prevalence of diabetes.
  • Healthcare expenditures for managing pediatric diabetes require ongoing monitoring and evaluation.
Abstract

Related Concept Videos

Diabetes Mellitus: Type 2 and Gestational01:22

Diabetes Mellitus: Type 2 and Gestational

Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
Diabetes Mellitus: Overview and Type I Subtype01:22

Diabetes Mellitus: Overview and Type I Subtype

Diabetes mellitus is a chronic metabolic disorder characterized by high blood glucose levels due to inadequate insulin production, insulin resistance, or both. The condition affects millions worldwide and can significantly impact their health and quality of life.
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
Diabetes: Management and Pharmacotherapy01:15

Diabetes: Management and Pharmacotherapy

The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Pathophysiology of Diabetes01:20

Pathophysiology of Diabetes

Diabetes mellitus is a chronic metabolic disorder characterized by hyperglycemia. The four categories of diabetes are type 1 diabetes, type 2 diabetes, other specific types of diabetes, and gestational diabetes.
Type 1 diabetes is characterized by autoimmune-mediated destruction of pancreatic β cells, with environmental factors potentially triggering this process in genetically susceptible individuals. Despite many not having a family history, certain genes increase susceptibility, suggesting a...
Insulin: Dosing Regimen and Adverse Effects01:16

Insulin: Dosing Regimen and Adverse Effects

Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
Diabetes: Symptoms, Diagnosis, and Complications01:15

Diabetes: Symptoms, Diagnosis, and Complications

For most patients, experiencing several weeks of polyuria, polydipsia, fatigue, and significant weight loss may indicate the presence of diabetes. Furthermore, adults displaying the phenotypic appearance of type 2 diabetes (particularly those who are obese and not initially insulin-requiring), may have islet cell autoantibodies, suggesting autoimmune-mediated β cell destruction and a diagnosis of latent autoimmune diabetes of adults (LADA). The categorization of glucose homeostasis is based on...